
    
      This is a study utilizing a prospective cohort design. Patients with Prostrate cancer (PCa)
      who are prescribed Lupron will be entered into the study cohort and will be followed for a
      maximum of 18 months with recommended assessments at 3, 6, 12 and 18 months after Day 1.
      Treatment of the patients and follow up will be according to the physicians' judgment,
      regional regulations and the product monograph.
    
  